Cargando…

Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization

BACKGROUND AND OBJECTIVES: Whether chronic autoimmune inflammatory diseases causally affect the risk of Alzheimer disease (AD) is controversial. We characterized the relationship between inflammatory diseases and risk of AD and explored the role of circulating inflammatory biomarkers in the relation...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jian, Su, Bowen, Karhunen, Ville, Gill, Dipender, Zuber, Verena, Ahola-Olli, Ari, Palaniswamy, Saranya, Auvinen, Juha, Herzig, Karl-Heinz, Keinänen-Kiukaanniemi, Sirkka, Salmi, Marko, Jalkanen, Sirpa, Lehtimäki, Terho, Salomaa, Veikko, Raitakari, Olli T., Matthews, Paul M., Elliott, Paul, Tsilidis, Konstantinos K., Jarvelin, Marjo-riitta, Tzoulaki, Ioanna, Dehghan, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946179/
https://www.ncbi.nlm.nih.gov/pubmed/36384659
http://dx.doi.org/10.1212/WNL.0000000000201489
_version_ 1784892280098783232
author Huang, Jian
Su, Bowen
Karhunen, Ville
Gill, Dipender
Zuber, Verena
Ahola-Olli, Ari
Palaniswamy, Saranya
Auvinen, Juha
Herzig, Karl-Heinz
Keinänen-Kiukaanniemi, Sirkka
Salmi, Marko
Jalkanen, Sirpa
Lehtimäki, Terho
Salomaa, Veikko
Raitakari, Olli T.
Matthews, Paul M.
Elliott, Paul
Tsilidis, Konstantinos K.
Jarvelin, Marjo-riitta
Tzoulaki, Ioanna
Dehghan, Abbas
author_facet Huang, Jian
Su, Bowen
Karhunen, Ville
Gill, Dipender
Zuber, Verena
Ahola-Olli, Ari
Palaniswamy, Saranya
Auvinen, Juha
Herzig, Karl-Heinz
Keinänen-Kiukaanniemi, Sirkka
Salmi, Marko
Jalkanen, Sirpa
Lehtimäki, Terho
Salomaa, Veikko
Raitakari, Olli T.
Matthews, Paul M.
Elliott, Paul
Tsilidis, Konstantinos K.
Jarvelin, Marjo-riitta
Tzoulaki, Ioanna
Dehghan, Abbas
author_sort Huang, Jian
collection PubMed
description BACKGROUND AND OBJECTIVES: Whether chronic autoimmune inflammatory diseases causally affect the risk of Alzheimer disease (AD) is controversial. We characterized the relationship between inflammatory diseases and risk of AD and explored the role of circulating inflammatory biomarkers in the relationships between inflammatory diseases and AD. METHODS: We performed observational analyses for chronic autoimmune inflammatory diseases and risk of AD using data from 2,047,513 participants identified in the UK Clinical Practice Research Datalink (CPRD). Using data of a total of more than 1,100,000 individuals from 15 large-scale genome-wide association study data sets, we performed 2-sample Mendelian randomizations (MRs) to investigate the relationships between chronic autoimmune inflammatory diseases, circulating inflammatory biomarker levels, and risk of AD. RESULTS: Cox regression models using CPRD data showed that the overall incidence of AD was higher among patients with inflammatory bowel disease (hazard ratio [HR] 1.17; 95% CI 1.15–1.19; p = 2.1 × 10(−4)), other inflammatory polyarthropathies and systematic connective tissue disorders (HR 1.13; 95% CI 1.12–1.14; p = 8.6 × 10(−5)), psoriasis (HR 1.13; 95% CI 1.10–1.16; p = 2.6 × 10(−4)), rheumatoid arthritis (HR 1.08; 95% CI 1.06–1.11; p = 4.0 × 10(−4)), and multiple sclerosis (HR 1.06; 95% CI 1.04–1.07; p = 2.8 × 10(−4)) compared with the age (±5 years) and sex-matched comparison groups free from all inflammatory diseases under investigation. Bidirectional MR analysis identified relationships between chronic autoimmune inflammatory diseases and circulating inflammatory biomarkers. Particularly, circulating monokine induced by gamma interferon (MIG) level was suggestively associated with a higher risk of AD (odds ratio from inverse variance weighted [OR(IVW)] 1.23; 95% CI 1.06–1.42; p(IVW) = 0.007) and lower risk of Crohn disease (OR(IVW) 0.73; 95% CI −0.62 to 0.86; p(IVW) = 1.3 × 10(−4)). Colocalization supported a common causal single nucleotide polymorphism for MIG and Crohn disease (posterior probability = 0.74), but not AD (posterior probability = 0.03). Using a 2-sample MR approach, genetically predicted risks of inflammatory diseases were not associated with higher AD risk. DISCUSSION: Our data suggest that the association between inflammatory diseases and risk of AD is unlikely to be causal and may be a result of confounding. In support, although inflammatory biomarkers showed evidence for causal associations with inflammatory diseases, evidence was weak that they affected both inflammatory disease and AD.
format Online
Article
Text
id pubmed-9946179
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99461792023-02-23 Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization Huang, Jian Su, Bowen Karhunen, Ville Gill, Dipender Zuber, Verena Ahola-Olli, Ari Palaniswamy, Saranya Auvinen, Juha Herzig, Karl-Heinz Keinänen-Kiukaanniemi, Sirkka Salmi, Marko Jalkanen, Sirpa Lehtimäki, Terho Salomaa, Veikko Raitakari, Olli T. Matthews, Paul M. Elliott, Paul Tsilidis, Konstantinos K. Jarvelin, Marjo-riitta Tzoulaki, Ioanna Dehghan, Abbas Neurology Research Article BACKGROUND AND OBJECTIVES: Whether chronic autoimmune inflammatory diseases causally affect the risk of Alzheimer disease (AD) is controversial. We characterized the relationship between inflammatory diseases and risk of AD and explored the role of circulating inflammatory biomarkers in the relationships between inflammatory diseases and AD. METHODS: We performed observational analyses for chronic autoimmune inflammatory diseases and risk of AD using data from 2,047,513 participants identified in the UK Clinical Practice Research Datalink (CPRD). Using data of a total of more than 1,100,000 individuals from 15 large-scale genome-wide association study data sets, we performed 2-sample Mendelian randomizations (MRs) to investigate the relationships between chronic autoimmune inflammatory diseases, circulating inflammatory biomarker levels, and risk of AD. RESULTS: Cox regression models using CPRD data showed that the overall incidence of AD was higher among patients with inflammatory bowel disease (hazard ratio [HR] 1.17; 95% CI 1.15–1.19; p = 2.1 × 10(−4)), other inflammatory polyarthropathies and systematic connective tissue disorders (HR 1.13; 95% CI 1.12–1.14; p = 8.6 × 10(−5)), psoriasis (HR 1.13; 95% CI 1.10–1.16; p = 2.6 × 10(−4)), rheumatoid arthritis (HR 1.08; 95% CI 1.06–1.11; p = 4.0 × 10(−4)), and multiple sclerosis (HR 1.06; 95% CI 1.04–1.07; p = 2.8 × 10(−4)) compared with the age (±5 years) and sex-matched comparison groups free from all inflammatory diseases under investigation. Bidirectional MR analysis identified relationships between chronic autoimmune inflammatory diseases and circulating inflammatory biomarkers. Particularly, circulating monokine induced by gamma interferon (MIG) level was suggestively associated with a higher risk of AD (odds ratio from inverse variance weighted [OR(IVW)] 1.23; 95% CI 1.06–1.42; p(IVW) = 0.007) and lower risk of Crohn disease (OR(IVW) 0.73; 95% CI −0.62 to 0.86; p(IVW) = 1.3 × 10(−4)). Colocalization supported a common causal single nucleotide polymorphism for MIG and Crohn disease (posterior probability = 0.74), but not AD (posterior probability = 0.03). Using a 2-sample MR approach, genetically predicted risks of inflammatory diseases were not associated with higher AD risk. DISCUSSION: Our data suggest that the association between inflammatory diseases and risk of AD is unlikely to be causal and may be a result of confounding. In support, although inflammatory biomarkers showed evidence for causal associations with inflammatory diseases, evidence was weak that they affected both inflammatory disease and AD. Lippincott Williams & Wilkins 2023-02-07 /pmc/articles/PMC9946179/ /pubmed/36384659 http://dx.doi.org/10.1212/WNL.0000000000201489 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Huang, Jian
Su, Bowen
Karhunen, Ville
Gill, Dipender
Zuber, Verena
Ahola-Olli, Ari
Palaniswamy, Saranya
Auvinen, Juha
Herzig, Karl-Heinz
Keinänen-Kiukaanniemi, Sirkka
Salmi, Marko
Jalkanen, Sirpa
Lehtimäki, Terho
Salomaa, Veikko
Raitakari, Olli T.
Matthews, Paul M.
Elliott, Paul
Tsilidis, Konstantinos K.
Jarvelin, Marjo-riitta
Tzoulaki, Ioanna
Dehghan, Abbas
Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title_full Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title_fullStr Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title_full_unstemmed Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title_short Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization
title_sort inflammatory diseases, inflammatory biomarkers, and alzheimer disease: an observational analysis and mendelian randomization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946179/
https://www.ncbi.nlm.nih.gov/pubmed/36384659
http://dx.doi.org/10.1212/WNL.0000000000201489
work_keys_str_mv AT huangjian inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT subowen inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT karhunenville inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT gilldipender inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT zuberverena inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT aholaolliari inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT palaniswamysaranya inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT auvinenjuha inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT herzigkarlheinz inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT keinanenkiukaanniemisirkka inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT salmimarko inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT jalkanensirpa inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT lehtimakiterho inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT salomaaveikko inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT raitakariollit inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT matthewspaulm inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT elliottpaul inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT tsilidiskonstantinosk inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT jarvelinmarjoriitta inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT tzoulakiioanna inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization
AT dehghanabbas inflammatorydiseasesinflammatorybiomarkersandalzheimerdiseaseanobservationalanalysisandmendelianrandomization